News
LSDI
0.8699
+12.25%
0.0949
Psychedelic drug developers could benefit from NIH funding for chronic pain
Healthcare Psychedelic drug developers could benefit from NIH funding for chronic pain. National Institutes of Health is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for pain. The research can include psilocybin, LSD, mescaline, and MDMA.
Seeking Alpha · 1d ago
Weekly Report: what happened at LSDI last week (0422-0426)?
Weekly Report · 1d ago
Scott Reeves Resigns from Lucy Scientific Discovery Board
TipRanks · 04/23 10:13
Weekly Report: what happened at LSDI last week (0415-0419)?
Weekly Report · 04/22 10:40
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
Weekly Report: what happened at LSDI last week (0408-0412)?
Weekly Report · 04/15 10:33
Weekly Report: what happened at LSDI last week (0401-0405)?
Weekly Report · 04/08 10:36
Weekly Report: what happened at LSDI last week (0325-0329)?
Weekly Report · 04/01 10:36
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Weekly Report: what happened at LSDI last week (0318-0322)?
Weekly Report · 03/25 10:38
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
12 Health Care Stocks Moving In Monday's After-Market Session
Ontrak (NASDAQ:OTRK) stock increased by 61.0% to $0.31 during Monday's after-market session. Universe Pharmaceuticals (NASdaq:UPC) shares rose 30.26% in the same session. Augmedix and Sophia Genetics also moved upwards. Losers Acurx Pharmaceuticals, Acutus Medical and Fresh2 Group were among the names in the losers.
Benzinga · 03/18 21:33
Weekly Report: what happened at LSDI last week (0311-0315)?
Weekly Report · 03/18 10:36
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Jabil Inc. Shares dipped 14.2% to $126.56 on Friday. The company reported financial second-quarter results and issued FY25 guidance below estimates. Verb Technology Company, Inc. (NASDAQ:VERB) shares jumped 189% in today's mid-day session.
Benzinga · 03/15 18:31
12 Health Care Stocks Moving In Friday's Intraday Session
Better Therapeutics shares increased by 65.4% to $0.06 during Friday's regular session. Carmell shares rose 38.52% and P3 Health Partners stock increased by 38.23%. Akebia Therapeutic shares rose by 28.1% during the regular session to $1.75.
Benzinga · 03/15 17:31
VERI, STI and VERB among mid-day movers
Verb Technology Company (VERB) and Geron Corp. Among mid-day movers. Groupon, C3is and Urgently are among the companies that lost ground. VERI, STI and VERB among the biggest gainers on the day.
Seeking Alpha · 03/15 16:52
Geron, Graphite Bio, Immuneering among healthcare movers
Healthcare On the Move: Geron, Graphite Bio, Immuneering among healthcare movers. S&P 500 Health Care Sector -0.46% to 1688.46. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 03/15 14:00
Nasdaq Down Over 100 Points; Hibbett Reports Downbeat Sales
U.S. Stocks traded lower on Friday. The Dow traded down 0.28% while the NASDAQ fell 0.67%. Hibbett Inc reported downbeat fourth-quarter sales and issued weak guidance. Verb Technology Company, Inc. Shares shot up 156% on Friday; energy shares jumped by 0.6%. Asian markets closed mostly lower in Asia Pacific markets.
Benzinga · 03/15 13:58
12 Health Care Stocks Moving In Friday's Pre-Market Session
Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. Madrigal Pharmaceuticals shares moved upwards by 22.34%. Akebia Therapeutic and Rallybio both reported better than expected Q4 earnings.
Benzinga · 03/15 13:06
COIN, MSTR and LSDI among pre-market losers
On the Move COIN, MSTR and LSDI among pre-market losers. Lucy Scientific Discovery (LSDI) -27%. Kopin Corp. (KOPN) -17% after Q4 earnings release. Adobe (ADBE) and Jabil (JBL) also among the losers.
Seeking Alpha · 03/15 12:20
More
Webull provides a variety of real-time LSDI stock news. You can receive the latest news about Lucy Scientific through multiple platforms. This information may help you make smarter investment decisions.
About LSDI
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.